Robert G. Veligdan, D.M.D., and VELscope Oral Cancer Screening
A highly regarded dental professional operating out of a private office in New York City, Robert G. Veligdan, D.M.D., provides patients with a full range of oral healthcare services, utilizing more than 35 years of clinical experience in his practice. With an extensive background in oral surgery, as well as general and cosmetic dentistry, Dr. Veligdan offers a host of preventative and restorative treatment options to his client base, including routine exams and cleanings, tooth restorations, teeth whitening, wisdom teeth extractions, root amputation, gum grafting, and VELscope oral cancer screening. A highly effective diagnostic tool used to detect cancerous growths in mouth tissue, VELscope oral cancer screening allows dentists to identify numerous forms of mucosal tissue abnormalities, such as signs of early-stage cancer on the lips and upper throat.
An entirely non-invasive procedure that requires less than five minutes to complete, VELscope oral cancer screening employs a blue light to illuminate the mouth and throat’s deep recesses. By stimulating naturally occurring fluorophores on the surface of the external oral membrane, VELscope optimally enhances visual contrast between healthy and potentially cancerous tissue. Implemented with notable success by more than 6,000 dentists in the United States and abroad, VELscope oral cancer screening has garnered the approval of the World Health Organization based on over six million clinical and in-office trials. Most often used to compliment a standard oral soft tissue examination, VELscope oral cancer screening utilizes technologies that have been applied in magnetic resonance imaging (MRI), computerized axial tomography (CAT), positron emission tomography (PET), panoramic radiography, and ultrasound machines.
VELscope oral cancer screening also performed well in a recent study performed at the University of Washington School of Dentistry. In a group of 620 patients, researchers discovered numerous forms of abnormal lesions, growths that would be impossible to detect without VELscope. These growths were identified as tumors on the salivary glands, squamous papillomas, bacterial, viral, and fungal infections, and lichenoid-related inflammations. The risk of obtaining a false positive with VELscope oral cancer screening is minimal, decreasing stress for patients and doctors alike. Further literature about VELscope oral cancer screening is available at www.velscope.com.